

Quince Therapeutics to Acquire EryDel

July 24, 2023

Forward-looking statements

Statements in this presentation contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as "believe," "may," "should," "expect," "anticipate," "plan," "believe," "estimated," "potential," "intend," "will," "can," "seek," or other similar words. Examples of forward-looking statements include, among others, statements relating to Quince's acquisition of EryDel; the timing of the closing of the transaction; the expected benefits of the transaction, including the continued current and future clinical development and potential expansion of EryDel assets, related platform, and related timing and costs; the strategic development path for EryDex; planned FDA and EMA submissions and clinical trials and timeline, prospects, and milestone expectations; the timing and success of the clinical trials and related data, including plans and the ability to initiate, fund, conduct and/or complete current and additional studies; the potential therapeutic benefits, safety, and efficacy of EryDex; statements about its ability to obtain, and the timing relating to, further development of EryDex, regulatory submissions and interactions with regulators; therapeutic and commercial potential; the integration of EryDel's business, operations, and employees into Quince; Quince's future development plans and related timing; its cash position and projected cash runway; the company's focus, objectives, plans, and strategies; and the ability to execute on any strategic transactions. Forward-looking statements are based on Quince's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forwardlooking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled "Risk Factors" in the company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 15, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince undertakes no duty to update such information except as required under applicable law.



Transformative acquisition with value-creating clinical milestones

- Phase 3 lead asset EryDex targets Ataxia-Telangiectasia (A-T) with no currently approved treatments and estimated \$1+ billion peak sales opportunity
- EryDex designed for controlled, slow release of dexamethasone over several weeks without long-term toxicity typically associated with chronic steroid administration
- Plan to enroll first patient in global Phase 3 trial of EryDex in second quarter of 2024 with NDA submission targeted by end of 2025, assuming positive study results
- Well-capitalized into 2026 with ability to fully fund EryDex expected through Phase 3 trial and to NDA submission, assuming positive study results







EryDel significant achievements

- 20+ years of work on autologous intracellular drug encapsulation (AIDE) technology platform
- > \$100+ million invested since founding out of University of Urbino, Italy
- > EryDex designated as orphan drug for A-T treatment from FDA and EMA
- Special protocol assessment (SPA) in place with FDA for single Phase 3 clinical trial of EryDex sufficient for NDA submission, assuming positive study results
- EryDex efficacy and safety profile demonstrated in prior Phase 3 clinical trial of A-T patients

 \bigcirc

Open label extension (OLE) and compassionate use data demonstrates up to 10+ years of chronic steroid administration without typical safety issues

Headquarters

• Bresso, Italy

Manufacturing

• Medolla, Italy

Leadership

- Luca Benatti: CEO
- Guenter Janhofer: CMO
- Giovanni Mambrini: COO
- Thomas Sabia: CCO

Employees

EryDel acquisition transaction details

		•
$(\mathbf{O}\mathbf{V})$	erv	iew

- Stock-for-stock upfront exchange of Quince stock and potential downstream milestone cash payments of up to **\$485 million**
 - Up to \$5 million in development milestones
 - \$25 million at NDA acceptance
 - \$60 million in approval milestones
 - \$395 million in market and sales milestones
 - No royalties paid to EryDel stockholders

() Unanimously approved by both companies' Board of Directors

EryDel stockholders to own maximum of approximately 16.7% of combined company – subject to downward adjustment

Governance & Leadership

- David Lamond remains Chairperson of Quince Board of Directors
- Dirk Thye remains Quince Chief Executive Officer and Director
- Quince Board of Directors expanded with addition of EryDel representative Luca Benatti

Structure

- > EryDel to operate as wholly owned subsidiary of Quince with ongoing presence in Italy
- > Retain EryDel team and keep organization intact
- Assumption of \$13 million (€10 million principal) EIB loan with scheduled payments beginning in the second half of 2026

Approvals & Closing

- Subject to certain regulatory approvals and other closing conditions
- > Expected to close in third quarter 2023



Autologous intracellular drug encapsulation (AIDE) technology

> Unique drug/device combination enables automated process for autologous intracellular drug encapsulation

> Platform capable of expansion to other drugs or biologics, including enzyme replacement therapy





Fully automated autologous point-of-care treatment



Bedside Blood Collection

- Patient's blood collected at the point-of-care for fully automated bedside procedure completed within two hours
- Erythrocytes loaded onto the Red Cell Loader using EryKit





- > Erythrocytes swollen and pores opened via multiple steps using series of process solutions, then dexamethasone added
- > Dexamethasone loaded erythrocytes washed, isolated, and prepared and then reinfused into patient




Encapsulated Drug Re-Infusion

- Designed for improved drug benefits including:
 - Slow, controlled release
 - Prolonged half-life

- Improved biodistribution
- Mitigates steroid toxicity



No currently approved treatments for A-T patients



A-T is an inherited neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene

> Approximately 10,000 A-T patients in U.S., U.K., and EU4 countries

Neurological symptoms worsen until patients are wheelchair-bound, usually by adolescence

Median lifespan of approximately 25 years, with mortality due to infections and malignancy

Currently no approved treatments for A-T and no known effective approaches to delay progression of disease



EryDex efficacy and safety profile demonstrated in prior clinical trial



Completed largest global study of A-T patients in Phase 3 ATTeST clinical trial and OLE

- Double-blind, placebo-controlled study (N=175) over 6-month treatment period with 12-month OLE (N=104)
- Patients randomized 1:1:1 to EryDex low dose, high dose, or placebo
- Primary endpoint: mICARS Secondary endpoints: CGI-C QOL VABS
- EryDex slowed neurological deterioration in all ages of A-T patients with statistically significant effect in 6 to 9 year subgroup
- > 12-month safety analysis demonstrated EryDex well-tolerated with no major adverse events typically associated with chronic steroid administration
- > Pursuing regulatory activities related to partial clinical hold in U.S. related to EryKit treatment consumables, in addition to activities to support potential MAA submission of EryDex
 - CE mark already obtained in Europe for treatment device and consumables kit



Note: mICARS = Modified International Cooperative Ataxia Rating Scale • CGI-C = Clinical Global Impression - Change • QOL = Quality of Life • VABS = Vineland Adaptive Behavior Scales

EryDex treatment slows neurological deterioration in all ages of A-T patients



ATTeST Primary Endpoint (All Ages) in Intent to Treat (ITT) Population



Note: mICARS = Modified International Cooperative Ataxia Rating Scale by Central Rater • LSM = Least Square Means

EryDex treatment showed statistically significant effect in 6 to 9 year subgroup



Primary population selected for Phase 3 NEAT clinical trial


ATTeST 6-9 Year Subgroup, mICARS



Note: mICARS = Modified International Cooperative Ataxia Rating Scale by Local Rater • LSM = Least Square Means

EryDex consistent and statistically significant in 6 to 9 year subgroup across multiple endpoints





Note: Values reflect Least Square Means (LSM) difference from placebo and the P value presented • ICARS = International Cooperative Ataxia Rating Scale – by Central Rater (CR) and Local Rater (LR) • mICARS = Modified International Cooperative Ataxia Rating Scale – by Central Rater (CR) and Local Rater (LR) • RmICARS = Rescored Modified International Cooperative Ataxia Rating Scale – by Central Rater (CR) and Local Rater (LR) • mICARS = Rescored Modified International Cooperative Ataxia Rating Scale – by Central Rater (CR) and Local Rater (LR) • RmICARS = Rescored Modified International Cooperative Ataxia Rating Scale – by Central Rater (CR) and Local Rater (LR) • RmICARS = Rescored Modified International Cooperative Ataxia Rating Scale – by Central Rater (CR) and Local Rater (LR) • RmICARS = Rescored Modified International Cooperative Ataxia Rating Scale – by Central Rater (CR) and Local Rater (LR) • RmICARS = Rescored Modified International Cooperative Ataxia Rating Scale – by Central Rater (CR) and Local Rater (LR) • RmICARS = Rescored Modified International Cooperative Ataxia Rating Scale – by Central Rater (CR) and Local Rater (LR) • RmICARS = Rescored Modified International Cooperative Ataxia Rating Scale – by Central Rater (CR) and Local Rater (LR) • RmICARS = Rescored Modified International Cooperative Ataxia Rating Scale – by Central Rater (CR) and Local Rater (LR) • RmICARS = Rescored Modified International Cooperative Ataxia Rating Scale – by Central Rater (CR) and Local Rater (LR) • RmICARS = Rescored Modified International Cooperative Ataxia Rating Scale – by Central Rater (CR) and Local Rater (LR) • RmICARS = Rescored Modified International Cooperative Ataxia Rating Scale – by Central Rater (CR) and Local Rater (LR) • RmICARS = Rescored Modified International Cooperative Ataxia Rating Scale – by Central Rater (R) • RmICARS = Rescored Modified International Cooperative Ataxia Rating Scale – by Central Rater (R) • RmICARS = Rescored Modified International Cooperative Ataxia Rating Scale – by Central

No clinically meaningful adverse events with EryDex, including those typically associated with chronic steroid treatment



	ATTeST: Initial Treatment Period			ATTeST: Through Month 12		
	EDS-EP Low Dose (N=59)	EDS-EP High Dose (N=57)	Placebo (N=59)	EDS-EP Low Dose (N=59)	EDS-EP High Dose (N=57)	Non-switch Placebo (N=19)
Patients With Any TEAE (%)	73%	82%	73%	76%	88%	79%
Patients With Any Treatment-Related TEAE (%)	25%	37%	25%	32%	44%	26%
Patients With Any Serious TEAE (%)	10%	12%	12%	14%	16%	21%
Patients With Any Serious Treatment-Related TEAE (%)	0	2%	0	2%	2%	5%
Patients With Any TEAE Leading to Discontinuation (%)	0	4%	0	2%	4%	0
Patients With Any TEAE Leading to Death (%)	0	0	0	0	0	0




Phase 3 NEAT study design under SPA

- Double-blind, randomized, placebo-controlled study over 6-month treatment period Plan to enroll first patient in global Phase 3 NEAT clinical trial of EryDex in second quarter 2024
- > Plan to enroll approximately 86 A-T patients ranging in age from 6 to 9 years-old Up to an additional 20 patients aged 10 or over to be included for potential broader label
- Patients randomized to EryDex or placebo Patient will be transitioned to expanded access program (EAP) after trial completion

Primary endpoint - RmICARS (FDA) Plan to collect mICARS (EMA) data as supporting data

Secondary endpoints – CGI-S • CGI-C • EuroQol





Note: RmICARS = Rescored Modified International Cooperative Ataxia Rating Scale • mICARS = Modified International Cooperative Ataxia Rating Scale • CGI-S = Clinical Global Impression – Severity • CGI-C = Clinical Global Impres

EryDex attractive commercial and rapid expansion potential

\$1+ billion estimated peak global sales opportunity for A-T indication alone

EryDex for A-T

- Approximately 10,000 A-T patients suffering from rare and debilitating pediatric disease in U.S., U.K., and EU4 countries with no currently approved therapies
- First-to-market potential with attractive pricing comparables and no known late-stage competition
- Designated as orphan drug for A-T treatment from FDA and EMA
- \bigcirc IP exclusivity until at least 2034 globally and at least 2035 in the U.S.

Rare and debilitating disease potential expansion

Target additional indications where chronic steroid treatment is the standard of care – or could be without long-term toxicity



Well-capitalized into 2026 with ability to fully fund EryDex expected through Phase 3 trial to NDA submission, assuming positive study results

Strong balance sheet with approximately \$87.6 million in cash, cash equivalents, and short term investments as of June 30, 2023 (unaudited)

Capital efficient development plan funds:

- EryDex Phase 3 NEAT study and NDA submission, assuming positive study results
- European regulatory activities related to potential MAA submission of EryDex

Potential out-licensing of ex-U.S. regional territories to provide runway through approval



Seasoned leadership team



CEO

Dirk Thye, M.D.

- 20+ years of experience in biotech company creation, R&D and executive leadership
- · Agenovir, Cidara, Cerexa and Peninsula



Guenter Janhofer, M.D., Ph.D.

- 30+ years of healthcare industry experience in roles of increasing complexity and scope
- Previously CMO at EryDel and CMO at BTG (acquired by Boston) Scientific for \$4.2B)

• 20+ years of drug commercialization and development experience

Spark Therapeutics (a Roche Company), Sobi, CSL Behring, Sanofi

across large, midsize, and small biotech organizations



CCO

EryDel, BTG, Merck

Thomas Sabia, M.B.A.



Brendan Hannah, M.B.A.

- 15+ years leading biotech BD, finance, and business operations
- Led BD at Agenovir (acquired by Vir for up to \$290M)
- Involved in \$1B+ in transactions



Giovanni Mambrini, MSc

- 20+ years of medical device technology experience with crossfunctional expertise in bringing complex programs to market
- Co-founded EryDel with prior experience at Covidien, Dideco, Livanova

Collective experience includes 20+ regulatory approvals and more than \$10 billion in aggregate transactions



Key clinical and corporate milestones

	Second half of 2023	2024	2025		
\bigcirc	Close acquisition of EryDel in third quarter 2023	Enroll first patient in Phase 3 NEAT clinical trial in second quarter 2024	> Phase 3 NEAT clinical trial topline results		
\Diamond	Target resolution of partial clinical hold on improved EryKit treatment consumables in U.S.	Initiate pediatric study plan	Target EryDex NDA submission with FDA by end of 2025, assuming positive study results		
\bigcirc	Initiate start up activities for Phase 3 NEAT clinical trial	Determine additional indications for EryDex and initiate R&D activities	At least one Phase 2 study of EryDex follow on indication		
\bigcirc	Pursue European regulatory activities related to potential MAA submission of EryDex	Initiate R&D activities for at least one additional program utilizing AIDE technology platform	Potential out-licensing of ex-U.S. regional territories to provide runway through approval		
•	Initiate start up activities for Phase 3 NEAT clinical trial Pursue European regulatory activities related to potential MAA submission of	 EryDex and initiate R&D activities Initiate R&D activities for at least one additional program utilizing AIDE 	 follow on indication Potential out-licensing of ex-U.S. regional territories to provide runw 		

Transformative acquisition with value-creating clinical milestones

- Phase 3 lead asset EryDex targets Ataxia-Telangiectasia (A-T) with no currently approved treatments and estimated \$1+ billion peak sales opportunity
- EryDex designed for controlled, slow release of dexamethasone over several weeks without long-term toxicity typically associated with chronic steroid administration
- Plan to enroll first patient in global Phase 3 trial of EryDex in second quarter of 2024 with NDA submission targeted by end of 2025, assuming positive study results
- Well-capitalized into 2026 with ability to fully fund EryDex expected through Phase 3 trial and to NDA submission, assuming positive study results





